Pharma & R&D
FDA Approves MannKind’s Inhaled Insulin for Children
By Intent.Health Team • May 29, 2026
What’s happening
The FDA approved MannKind Corporation's inhaled insulin for children with diabetes.
The treatment allows insulin to be inhaled rather than injected, providing another option for young patients who may struggle with regular injections.
What’s changing / Business impact
The approval expands treatment options in pediatric diabetes care and could increase adoption of alternative insulin delivery methods.
Why this matters
Many children dislike or fear frequent injections. Alternative delivery systems may improve treatment adherence and quality of life.